{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T05:19:39Z","timestamp":1790140779823,"version":"4.0.1"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:00:00Z","timestamp":1771459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:00:00Z","timestamp":1771459200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1038\/s41375-026-02894-6","type":"journal-article","created":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T09:12:35Z","timestamp":1771492355000},"page":"739-750","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["CD40\/PI3K\/FOXO1 axis rewiring drives microenvironment-dependent BIM silencing to sustain lymphoma growth and survival"],"prefix":"10.1038","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-7427-6060","authenticated-orcid":false,"given":"Candice","family":"Madiot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9line","family":"Bellanger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christelle","family":"Dousset","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salom\u00e9","family":"Decombis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Thirouard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonin","family":"Papin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5509-3086","authenticated-orcid":false,"given":"Estelle","family":"Baron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Barc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0095-6999","authenticated-orcid":false,"given":"Yannick","family":"Le Bris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Gomez-Bougie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agn\u00e8s","family":"Moreau-Aubry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7600-3329","authenticated-orcid":false,"given":"Benoit","family":"Tessoulin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6287-8148","authenticated-orcid":false,"given":"Catherine","family":"Pellat-Deceunynck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2199-752X","authenticated-orcid":false,"given":"David","family":"Chiron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,19]]},"reference":[{"key":"2894_CR1","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1016\/S0140-6736(24)00184-3","volume":"403","author":"M Dreyling","year":"2024","unstructured":"Dreyling M, Doorduijn J, Gin\u00e9 E, Jerkeman M, Walewski J, Hutchings M, et al. Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network. Lancet. 2024;403:2293\u2013306.","journal-title":"Lancet"},{"key":"2894_CR2","first-page":"877","volume":"137","author":"S Le Gouill","year":"2021","unstructured":"Le Gouill S, Morschhauser F, Chiron D, Bouabdallah K, Cartron G, Casasnovas O, et al. Ibrutinib, obinutuzumab, and venetoclax in relapsed and untreated patients with mantle cell lymphoma: a phase 1\/2 trial. Blood J Am Soc Hematol. 2021;137:877\u201387.","journal-title":"Blood J Am Soc Hematol"},{"key":"2894_CR3","doi-asserted-by":"publisher","first-page":"2442","DOI":"10.1038\/s41375-019-0463-3","volume":"33","author":"A Papin","year":"2019","unstructured":"Papin A, Tessoulin B, Bellanger C, Moreau A, Le Bris Y, Maisonneuve H, et al. CSF1R and BTK inhibitions as novel strategies to disrupt the dialog between mantle cell lymphoma and macrophages. Leukemia. 2019;33:2442\u201353.","journal-title":"Leukemia"},{"key":"2894_CR4","doi-asserted-by":"publisher","first-page":"2905","DOI":"10.3324\/haematol.2021.279800","volume":"107","author":"S Decombis","year":"2022","unstructured":"Decombis S, Papin A, Bellanger C, Sortais C, Dousset C, Le Bris Y, et al. The IL32\/BAFF axis supports prosurvival dialogs in the lymphoma ecosystem and is disrupted by NIK inhibition. Haematologica. 2022;107:2905\u201317.","journal-title":"Haematologica"},{"key":"2894_CR5","doi-asserted-by":"publisher","first-page":"3783","DOI":"10.1182\/blood-2012-04-424630","volume":"120","author":"L Zhang","year":"2012","unstructured":"Zhang L, Yang J, Qian J, Li H, Romaguera JE, Kwak LW, et al. Role of the microenvironment in mantle cell lymphoma: IL-6 is an important survival factor for the tumor cells. Blood. 2012;120:3783\u201392.","journal-title":"Blood"},{"key":"2894_CR6","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1182\/bloodadvances.2016004176","volume":"1","author":"KD Jayappa","year":"2017","unstructured":"Jayappa KD, Portell CA, Gordon VL, Capaldo BJ, Bekiranov S, Axelrod MJ, et al. Microenvironmental agonists generate de novo phenotypic resistance to combined ibrutinib plus venetoclax in CLL and MCL. Blood Adv. 2017;1:933\u201346.","journal-title":"Blood Adv"},{"key":"2894_CR7","doi-asserted-by":"publisher","first-page":"2808","DOI":"10.1182\/blood-2016-06-720490","volume":"128","author":"D Chiron","year":"2016","unstructured":"Chiron D, Bellanger C, Papin A, Tessoulin B, Dousset C, Maiga S, et al. Rational targeted therapies to overcome microenvironment-dependent expansion of mantle cell lymphoma. Blood. 2016;128:2808\u201318.","journal-title":"Blood"},{"key":"2894_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-017-0157-6","volume":"9","author":"H Rauert-Wunderlich","year":"2018","unstructured":"Rauert-Wunderlich H, Rudelius M, Berberich I, Rosenwald A. CD40L mediated alternative NF\u03baB-signaling induces resistance to BCR-inhibitors in patients with mantle cell lymphoma. Cell Death Dis. 2018;9:86.","journal-title":"Cell Death Dis"},{"key":"2894_CR9","doi-asserted-by":"crossref","unstructured":"Vareli A, Narayanan HV, Clark H, Jayawant E, Zhou H, Liu Y, et al. Systems biology-enabled targeting of NF-\u03ba\u0392 and BCL2 overcomes microenvironment-mediated BH3-mimetic resistance in DLBCL [Internet]. 2024 [cit\u00e9 20 juin 2025]. Disponible sur: http:\/\/biorxiv.org\/lookup\/doi\/10.1101\/2024.11.30.626166","DOI":"10.1101\/2024.11.30.626166"},{"key":"2894_CR10","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1182\/blood-2016-10-745059","volume":"129","author":"VA Gupta","year":"2017","unstructured":"Gupta VA, Matulis SM, Conage-Pough JE, Nooka AK, Kaufman JL, Lonial S, et al. Bone marrow microenvironment\u2013derived signals induce Mcl-1 dependence in multiple myeloma. Blood. 2017;129:1969\u201379.","journal-title":"Blood"},{"key":"2894_CR11","doi-asserted-by":"publisher","first-page":"645","DOI":"10.3389\/fonc.2018.00645","volume":"8","author":"B Tessoulin","year":"2019","unstructured":"Tessoulin B, Papin A, Gomez-Bougie P, Bellanger C, Amiot M, Pellat-Deceunynck C, et al. BCL2-family dysregulation in B-cell malignancies: from gene expression regulation to a targeted therapy biomarker. Front Oncol. 2019;8:645.","journal-title":"Front Oncol"},{"key":"2894_CR12","doi-asserted-by":"crossref","unstructured":"Decombis S, Bellanger C, Le Bris Y, Madiot C, Jardine J, Santos JC, et al. CARD11 gain of function upregulates BCL2A1 and promotes resistance to targeted therapies combination in B-cell lymphoma. Blood. 2023;142:1543\u201355.","DOI":"10.1182\/blood.2023020211"},{"key":"2894_CR13","doi-asserted-by":"publisher","first-page":"23058","DOI":"10.18632\/oncotarget.5492","volume":"6","author":"RV Sionov","year":"2015","unstructured":"Sionov RV, Vlahopoulos SA, Granot Z. Regulation of Bim in Health and Disease. Oncotarget. 2015;6:23058\u2013134.","journal-title":"Oncotarget"},{"key":"2894_CR14","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.humpath.2019.08.008","volume":"93","author":"JD Wang","year":"2019","unstructured":"Wang JD, Katz SG, Morgan EA, Yang DT, Pan X, Xu ML. Proapoptotic protein BIM as a novel prognostic marker in mantle cell lymphoma. Hum Pathol. 2019;93:54\u201364.","journal-title":"Hum Pathol"},{"key":"2894_CR15","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1182\/blood-2013-04-499079","volume":"123","author":"SG Katz","year":"2014","unstructured":"Katz SG, LaBelle JL, Meng H, Valeriano RP, Fisher JK, Sun H, et al. Mantle cell lymphoma in cyclin D1 transgenic mice with Bim-deficient B cells. Blood. 2014;123:884\u201393.","journal-title":"Blood"},{"key":"2894_CR16","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1038\/sj.onc.1208300","volume":"24","author":"H Tagawa","year":"2005","unstructured":"Tagawa H, Karnan S, Suzuki R, Matsuo K, Zhang X, Ota A, et al. Genome-wide array-based CGH for mantle cell lymphoma: identification of homozygous deletions of the proapoptotic gene BIM. Oncogene. 2005;24:1348\u201358.","journal-title":"Oncogene"},{"key":"2894_CR17","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1182\/blood-2006-06-026500","volume":"109","author":"C Mestre-Escorihuela","year":"2007","unstructured":"Mestre-Escorihuela C, Rubio-Moscardo F, Richter JA, Siebert R, Climent J, Fresquet V, et al. Homozygous deletions localize novel tumor suppressor genes in B-cell lymphomas. Blood. 2007;109:271\u201380.","journal-title":"Blood"},{"key":"2894_CR18","doi-asserted-by":"publisher","first-page":"4455","DOI":"10.1158\/1078-0432.CCR-18-3275","volume":"25","author":"D Prukova","year":"2019","unstructured":"Prukova D, Andera L, Nahacka Z, Karolova J, Svaton M, Klanova M, et al. Cotargeting of BCL2 with venetoclax and MCL1 with S63845 is synthetically lethal in vivo in relapsed mantle cell lymphoma. Clin Cancer Res. 2019;25:4455\u201365.","journal-title":"Clin Cancer Res"},{"key":"2894_CR19","doi-asserted-by":"publisher","first-page":"e909","DOI":"10.1097\/HS9.0000000000000909","volume":"7","author":"J Mateos-Jaimez","year":"2023","unstructured":"Mateos-Jaimez J, Mangolini M, Vidal A, Kulis M, Colomer D, Campo E, et al. Robust CRISPR-Cas9 genetic editing of primary chronic lymphocytic leukemia and mantle cell lymphoma cells. Hemasphere. 2023;7:e909.","journal-title":"Hemasphere"},{"key":"2894_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-47739-x","volume":"15","author":"M Baudic","year":"2024","unstructured":"Baudic M, Murata H, Bosada FM, Melo US, Aizawa T, Lindenbaum P, et al. TAD boundary deletion causes PITX2-related cardiac electrical and structural defects. Nat Commun. 2024;15:3380.","journal-title":"Nat Commun"},{"key":"2894_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-18035-1","volume":"11","author":"M Bentsen","year":"2020","unstructured":"Bentsen M, Goymann P, Schultheis H, Klee K, Petrova A, Wiegandt R, et al. ATAC-seq footprinting unravels kinetics of transcription factor binding during zygotic genome activation. Nat Commun. 2020;11:4267.","journal-title":"Nat Commun"},{"key":"2894_CR22","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1002\/hon.2750","volume":"38","author":"Y Le Bris","year":"2020","unstructured":"Le Bris Y, Magrangeas F, Moreau A, Chiron D, Gu\u00e9rin-Charbonnel C, Theisen O, et al. Whole genome copy number analysis in search of new prognostic biomarkers in first line treatment of mantle cell lymphoma. A study by the LYSA group. Hematol Oncol. 2020;38:446\u201355.","journal-title":"Hematol Oncol"},{"key":"2894_CR23","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1158\/1078-0432.CCR-13-0987","volume":"20","author":"JC Godbersen","year":"2014","unstructured":"Godbersen JC, Humphries LA, Danilova OV, Kebbekus PE, Brown JR, Eastman A, et al. The Nedd8-activating enzyme inhibitor MLN4924 thwarts microenvironment-driven NF-\u03baB activation and induces apoptosis in chronic lymphocytic leukemia B cells. Clin Cancer Res. 2014;20:1576\u201389.","journal-title":"Clin Cancer Res"},{"key":"2894_CR24","doi-asserted-by":"publisher","first-page":"W212","DOI":"10.1093\/nar\/gkz446","volume":"47","author":"AB Keenan","year":"2019","unstructured":"Keenan AB, Torre D, Lachmann A, Leong AK, Wojciechowicz ML, Utti V, et al. ChEA3: transcription factor enrichment analysis by orthogonal omics integration. Nucleic Acids Res. 2019;47:W212\u201324.","journal-title":"Nucleic Acids Res"},{"key":"2894_CR25","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1083\/jcb.200303026","volume":"162","author":"J Gilley","year":"2003","unstructured":"Gilley J, Coffer PJ, Ham J. FOXO transcription factors directly activate bim gene expression and promote apoptosis in sympathetic neurons. J Cell Biol. 2003;162:613\u201322.","journal-title":"J Cell Biol"},{"key":"2894_CR26","volume":"2014","author":"Y Wang","year":"2014","unstructured":"Wang Y, Zhou Y, Graves DT. FOXO transcription factors: their clinical significance and regulation. Biomed Res Int. 2014;2014:925350.","journal-title":"Biomed Res Int"},{"key":"2894_CR27","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1124\/mol.110.065714","volume":"78","author":"T Nagashima","year":"2010","unstructured":"Nagashima T, Shigematsu N, Maruki R, Urano Y, Tanaka H, Shimaya A, et al. Discovery of novel Forkhead Box O1 inhibitors for treating type 2 diabetes: improvement of fasting glycemia in diabetic db\/db mice. Mol Pharmacol. 2010;78:961\u201370.","journal-title":"Mol Pharmacol"},{"key":"2894_CR28","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1182\/blood-2015-06-654111","volume":"127","author":"M Szydlowski","year":"2016","unstructured":"Szydlowski M, Kiliszek P, Sewastianik T, Jablonska E, Bialopiotrowicz E, Gorniak P, et al. FOXO1 activation is an effector of SYK and AKT inhibition in tonic BCR signal-dependent diffuse large B-cell lymphomas. Blood. 2016;127:739\u201348.","journal-title":"Blood"},{"key":"2894_CR29","doi-asserted-by":"publisher","first-page":"45276","DOI":"10.1074\/jbc.M208063200","volume":"277","author":"X Zhang","year":"2002","unstructured":"Zhang X, Gan L, Pan H, Guo S, He X, Olson ST, et al. Phosphorylation of serine 256 suppresses transactivation by FKHR (FOXO1) by multiple mechanisms direct indirect Eff Nucl\/cytoplasmic shuttling DNA binding. J Biol Chem. 2002;277:45276\u201384.","journal-title":"J Biol Chem"},{"key":"2894_CR30","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1016\/S0092-8674(00)80595-4","volume":"96","author":"A Brunet","year":"1999","unstructured":"Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS, et al. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell. 1999;96:857\u201368.","journal-title":"Cell"},{"key":"2894_CR31","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1182\/blood-2021-151083","volume":"138","author":"Y Le Bris","year":"2021","unstructured":"Le Bris Y, M\u00e9nard A, Moreau A, Le Lan N, Bossard C, B\u00e9n\u00e9 MC. Single capture high throughput sequencing assay for combined V(D)J clonality analysis and oncogene mutations in the diagnosis of T and B lymphoid malignancies. Blood. 2021;138:2404.","journal-title":"Blood"},{"key":"2894_CR32","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1016\/j.molmed.2023.03.007","volume":"29","author":"D Ostroverkhova","year":"2023","unstructured":"Ostroverkhova D, Przytycka TM, Panchenko AR. Cancer driver mutations: predictions and reality. Trends Mol Med. 2023;29:554\u201366.","journal-title":"Trends Mol Med"},{"key":"2894_CR33","doi-asserted-by":"publisher","first-page":"D941","DOI":"10.1093\/nar\/gky1015","volume":"47","author":"JG Tate","year":"2019","unstructured":"Tate JG, Bamford S, Jubb HC, Sondka Z, Beare DM, Bindal N, et al. COSMIC: the Catalogue Of Somatic Mutations In Cancer. Nucleic Acids Res. 2019;47:D941\u20137.","journal-title":"Nucleic Acids Res"},{"key":"2894_CR34","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1001\/jamaoncol.2018.1660","volume":"4","author":"J Marquart","year":"2018","unstructured":"Marquart J, Chen EY, Prasad V. Estimation of the percentage of US patients with cancer who benefit from genome-driven oncology. JAMA Oncol. 2018;4:1093.","journal-title":"JAMA Oncol"},{"key":"2894_CR35","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.ccell.2023.02.016","volume":"41","author":"KE De Visser","year":"2023","unstructured":"De Visser KE, Joyce JA. The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth. Cancer Cell. 2023;41:374\u2013403.","journal-title":"Cancer Cell"},{"key":"2894_CR36","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/nrc3774","volume":"14","author":"DW Scott","year":"2014","unstructured":"Scott DW, Gascoyne RD. The tumour microenvironment in B cell lymphomas. Nat Rev Cancer. 2014;14:517\u201334.","journal-title":"Nat Rev Cancer"},{"key":"2894_CR37","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.immuni.2018.01.008","volume":"48","author":"W Luo","year":"2018","unstructured":"Luo W, Weisel F, Shlomchik MJ. B cell receptor and CD40 Signaling Are Rewired for Synergistic Induction of the c-Myc Transcription Factor in Germinal Center B Cells. Immunity. 2018;48:313\u2013326.e5.","journal-title":"Immunity"},{"key":"2894_CR38","doi-asserted-by":"crossref","unstructured":"Sarkozy C, Tessoulin B, Chiron D. Unraveling MCL biology to understand resistance and identify vulnerabilities. Blood. 2024;145:696\u2013707.","DOI":"10.1182\/blood.2023022351"},{"key":"2894_CR39","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1016\/j.ccell.2021.08.011","volume":"39","author":"CB Steen","year":"2021","unstructured":"Steen CB, Luca BA, Esfahani MS, Azizi A, Sworder BJ, Nabet BY, et al. The landscape of tumor cell states and ecosystems in diffuse large B cell lymphoma. Cancer Cell. 2021;39:1422\u20131437.e10.","journal-title":"Cancer Cell"},{"key":"2894_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00927-2","volume":"13","author":"P Jain","year":"2023","unstructured":"Jain P, Nomie K, Kotlov N, Segodin V, Hill H, Ok CY, et al. Immune-depleted tumor microenvironment is associated with poor outcomes and BTK inhibitor resistance in mantle cell lymphoma. Blood Cancer J. 2023;13:156.","journal-title":"Blood Cancer J"},{"key":"2894_CR41","doi-asserted-by":"publisher","first-page":"5141","DOI":"10.1182\/blood-2008-03-146704","volume":"112","author":"DYH Hallaert","year":"2008","unstructured":"Hallaert DYH, Jaspers A, Van Noesel CJ, Van Oers MHJ, Kater AP, Eldering E. c-Abl kinase inhibitors overcome CD40-mediated drug resistance in CLL: implications for therapeutic targeting of chemoresistant niches. Blood. 2008;112:5141\u20139.","journal-title":"Blood"},{"key":"2894_CR42","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/j.cell.2015.01.042","volume":"160","author":"J Montero","year":"2015","unstructured":"Montero J, Sarosiek KA, DeAngelo JD, Maertens O, Ryan J, Ercan D, et al. Drug-induced death signaling strategy rapidly predicts cancer response to chemotherapy. Cell. 2015;160:977\u201389.","journal-title":"Cell"},{"key":"2894_CR43","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1016\/j.ejca.2009.04.005","volume":"45","author":"E San Jos\u00e9-Eneriz","year":"2009","unstructured":"San Jos\u00e9-Eneriz E, Agirre X, Jim\u00e9nez-Velasco A, Cordeu L, Mart\u00edn V, Arqueros V, et al. Epigenetic down-regulation of BIM expression is associated with reduced optimal responses to imatinib treatment in chronic myeloid leukaemia. Eur J Cancer. 2009;45:1877\u201389.","journal-title":"Eur J Cancer"},{"key":"2894_CR44","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1182\/blood-2011-07-367417","volume":"119","author":"A Paterson","year":"2012","unstructured":"Paterson A, Mockridge CI, Adams JE, Krysov S, Potter KN, Duncombe AS, et al. Mechanisms and clinical significance of BIM phosphorylation in chronic lymphocytic leukemia. Blood. 2012;119:1726\u201336.","journal-title":"Blood"},{"key":"2894_CR45","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1093\/intimm\/dxr127","volume":"24","author":"Y Gao","year":"2012","unstructured":"Gao Y, Kazama H, Yonehara S. Bim regulates B-cell receptor-mediated apoptosis in the presence of CD40 signaling in CD40-pre-activated splenic B cells differentiating into plasma cells. Int Immunol. 2012;24:283\u201392.","journal-title":"Int Immunol"},{"key":"2894_CR46","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/s41392-021-00828-5","volume":"6","author":"Y He","year":"2021","unstructured":"He Y, Sun MM, Zhang GG, Yang J, Chen KS, Xu WW, et al. Targeting PI3K\/Akt signal transduction for cancer therapy. Sig Transduct Target Ther. 2021;6:425.","journal-title":"Sig Transduct Target Ther"},{"key":"2894_CR47","doi-asserted-by":"publisher","first-page":"e118","DOI":"10.1038\/bcj.2013.15","volume":"3","author":"M Reis-Sobreiro","year":"2013","unstructured":"Reis-Sobreiro M, Rou\u00e9 G, Moros A, Gajate C, De La Iglesia-Vicente J, Colomer D, et al. Lipid raft-mediated Akt signaling as a therapeutic target in mantle cell lymphoma. Blood Cancer J. 2013;3:e118.","journal-title":"Blood Cancer J"},{"key":"2894_CR48","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14920","volume":"8","author":"X Zhao","year":"2017","unstructured":"Zhao X, Lwin T, Silva A, Shah B, Tao J, Fang B, et al. Unification of de novo and acquired ibrutinib resistance in mantle cell lymphoma. Nat Commun. 2017;8:14920.","journal-title":"Nat Commun"},{"key":"2894_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-55728-9","volume":"14","author":"S Gambino","year":"2024","unstructured":"Gambino S, Quaglia FM, Galasso M, Cavallini C, Chignola R, Lovato O, et al. B-cell receptor signaling activity identifies patients with mantle cell lymphoma at higher risk of progression. Sci Rep. 2024;14:6595.","journal-title":"Sci Rep"},{"key":"2894_CR50","first-page":"1102","volume":"12","author":"S Huang","year":"2022","unstructured":"Huang S, Liu Y, Chen Z, Wang M, Jiang VC. PIK-75 overcomes venetoclax resistance via blocking PI3K-AKT signaling and MCL-1 expression in mantle cell lymphoma. Am J Cancer Res. 2022;12:1102\u201315.","journal-title":"Am J Cancer Res"},{"key":"2894_CR51","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1182\/blood-2006-04-015586","volume":"108","author":"M Rudelius","year":"2006","unstructured":"Rudelius M, Pittaluga S, Nishizuka S, Pham THT, Fend F, Jaffe ES, et al. Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma. Blood. 2006;108:1668\u201376.","journal-title":"Blood"},{"key":"2894_CR52","doi-asserted-by":"publisher","first-page":"5279","DOI":"10.1182\/bloodadvances.2024013205","volume":"8","author":"N Bettazova","year":"2024","unstructured":"Bettazova N, Senavova J, Kupcova K, Sovilj D, Rajmonova A, Andera L, et al. Impact of PIK3CA gain and PTEN loss on mantle cell lymphoma biology and sensitivity to targeted therapies. Blood Adv. 2024;8:5279\u201389.","journal-title":"Blood Adv"},{"key":"2894_CR53","doi-asserted-by":"publisher","first-page":"2274","DOI":"10.1182\/blood-2012-10-460832","volume":"121","author":"S Iyengar","year":"2013","unstructured":"Iyengar S, Clear A, B\u00f6d\u00f6r C, Maharaj L, Lee A, Calaminici M, et al. P110\u03b1-mediated constitutive PI3K signaling limits the efficacy of p110\u03b4-selective inhibition in mantle cell lymphoma, particularly with multiple relapse. Blood. 2013;121:2274\u201384.","journal-title":"Blood"},{"key":"2894_CR54","doi-asserted-by":"publisher","first-page":"3667","DOI":"10.1158\/1078-0432.CCR-24-0967","volume":"30","author":"SS Sk\u00e5nland","year":"2024","unstructured":"Sk\u00e5nland SS, Okkenhaug K, Davids MS. PI3K inhibitors in hematology: when one door closes. Clin Cancer Res. 2024;30:3667\u201375.","journal-title":"Clin Cancer Res"},{"key":"2894_CR55","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1182\/blood-2018-08-867499","volume":"133","author":"A Forero-Torres","year":"2019","unstructured":"Forero-Torres A, Ramchandren R, Yacoub A, Wertheim MS, Edenfield WJ, Caimi P, et al. Parsaclisib, a potent and highly selective PI3K\u03b4 inhibitor, in patients with relapsed or refractory B-cell malignancies. Blood. 2019;133:1742\u201352.","journal-title":"Blood"},{"key":"2894_CR56","doi-asserted-by":"publisher","DOI":"10.1172\/JCI173770","volume":"134","author":"L Ondrisova","year":"2024","unstructured":"Ondrisova L, Seda V, Hlavac K, Pavelkova P, Hoferkova E, Chiodin G, et al. FoxO1\/Rictor axis induces a nongenetic adaptation to ibrutinib via Akt activation in chronic lymphocytic leukemia. J Clin Investig. 2024;134:e173770.","journal-title":"J Clin Investig"},{"key":"2894_CR57","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1182\/blood.2020008101","volume":"138","author":"V Seda","year":"2021","unstructured":"Seda V, Vojackova E, Ondrisova L, Kostalova L, Sharma S, Loja T, et al. FoxO1-GAB1 axis regulates homing capacity and tonic AKT activity in chronic lymphocytic leukemia. Blood. 2021;138:758\u201372.","journal-title":"Blood"},{"key":"2894_CR58","doi-asserted-by":"publisher","DOI":"10.1172\/JCI160767","volume":"132","author":"JY Jang","year":"2022","unstructured":"Jang JY, Hwang I, Pan H, Yao J, Alinari L, Imada E, et al. A FOXO1-dependent transcription network is a targetable vulnerability of mantle cell lymphomas. J Clin Investig. 2022;132:e160767.","journal-title":"J Clin Investig"},{"key":"2894_CR59","doi-asserted-by":"crossref","unstructured":"Hlavac K, Pavelkova P, Ondrisova L, Mraz M. FoxO1 signaling in B cell malignancies and its therapeutic targeting. FEBS Lett. 2024;599:2911\u201331.","DOI":"10.1002\/1873-3468.15057"},{"key":"2894_CR60","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1002\/ajh.26523","volume":"97","author":"P Jain","year":"2022","unstructured":"Jain P, Wang ML. Mantle cell lymphoma in 2022\u2014A comprehensive update on molecular pathogenesis, risk stratification, clinical approach, and current and novel treatments. Am J Hematol. 2022;97:638\u201356.","journal-title":"Am J Hematol"},{"key":"2894_CR61","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1038\/nrc2714","volume":"9","author":"MB Meads","year":"2009","unstructured":"Meads MB, Gatenby RA, Dalton WS. Environment-mediated drug resistance: a major contributor to minimal residual disease. Nat Rev Cancer. 2009;9:665\u201374.","journal-title":"Nat Rev Cancer"},{"key":"2894_CR62","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1200\/JCO.23.02470","volume":"43","author":"TJ Phillips","year":"2025","unstructured":"Phillips TJ, Carlo-Stella C, Morschhauser F, Bachy E, Crump M, Trn\u011bn\u00fd M, et al. Glofitamab in relapsed\/refractory mantle cell lymphoma: results from a phase I\/II study. J Clin Oncol. 2025;43:318\u201328.","journal-title":"J Clin Oncol"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-02894-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-02894-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-02894-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T11:02:34Z","timestamp":1775559754000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-02894-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,19]]},"references-count":62,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["2894"],"URL":"https:\/\/doi.org\/10.1038\/s41375-026-02894-6","relation":{"is-basis-for":[{"id-type":"doi","id":"10.52843\/cassyni.md9vyk","asserted-by":"object"}]},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,19]]},"assertion":[{"value":"18 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}